A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study.
Qing ZhouLin WuPei HuTongtong AnJianying ZhouLi ZhangXiao-Qing LiuFeng LuoXin ZhengYing ChengNong YangJunling LiJifeng FengBaohui HanYong SongKai WangLi ZhangJian FangHong ZhaoYongqian ShuXiao-Yan LinZhihong ChenBin GanWan-Hong XuWei TangXiaoying ZhangJin-Ji YangXiao XuYi-Long WuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Abivertinib of 300 mg BID demonstrated favorable clinical efficacy with manageable side-effects in patients with EGFR T790M+NSCLC.